Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study

被引:17
|
作者
Yoon, Young Hee [1 ]
Kim, Ha Kyoung [2 ]
Yoon, Hee Seong [3 ]
Kang, Se Woong [4 ]
Kim, June-Gone [1 ]
Park, Kyu Hyung [5 ]
Jo, Young Joon [6 ]
Lee, Joo Yong [1 ]
Lee, Dong Hoon [1 ]
机构
[1] Univ Ulsan, Dept Ophthalmol, Asan Med Ctr, Seoul 138736, South Korea
[2] Hallym Univ, Dept Ophthalmol, Kangnam Sacred Heart Hosp, Seoul, South Korea
[3] St Marys Eye Clin, Pusan, South Korea
[4] Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Seoul, South Korea
[5] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Gyeonggi Do, South Korea
[6] Chungnam Natl Univ Hosp, Dept Ophthalmol, Taejon, South Korea
关键词
Retinal vein occlusion; Macular edema; Duration of symptom; Early treatment; Korean patients; INTRAVITREAL TRIAMCINOLONE; STANDARD-CARE; RISK-FACTORS; BRANCH; EFFICACY; SAFETY;
D O I
10.1007/s10384-014-0305-9
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
To determine the correlation between the duration of macular edema (ME) and visual outcomes among Korean patients with retinal vein occlusion (RVO). Multicenter, interventional case series. Treatment-naive patients (n = 249) with branch or central RVO (BRVO/CRVO) and ME for < 6 months were included. We assessed the correlation between the duration of ME and treatment outcomes including the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) improvement, the proportion of patients achieving at least a 3-line gain in BCVA, and the mean reduction in central retinal thickness (CRT) at 6 months. One hundred and fifty-six patients with BRVO and 93 patients with CRVO were divided into five groups based on the duration of ME (< 2, 2-4 weeks, 1-2, 2-3, 3-6 months); the mean baseline BCVA and CRT among the groups did not differ significantly. In BRVO, the mean logarithm of the minimum angle of resolution (logMAR) BCVA improvements in the groups were 0.51, 0.32, 0.17, 0.19, and 0.13, respectively (P = 0.002). The respective percentages of at least 3-line gains were 64, 53, 39, 38, and 21 % (P < 0.001). The BCVA didn't significantly improve in CRVO. The decrease in CRT was not correlated significantly with the duration of ME in either disease. Treatment of BRVO as early as 2 weeks after onset of ME enhanced the visual outcome; there was no correlation in the patients with CRVO. This finding supports the current trend favoring early treatment to obtain better visual outcomes in patients with BRVO.
引用
收藏
页码:146 / 154
页数:9
相关论文
共 50 条
  • [1] Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study
    Young Hee Yoon
    Ha Kyoung Kim
    Hee Seong Yoon
    Se Woong Kang
    June-Gone Kim
    Kyu Hyung Park
    Young Joon Jo
    Joo Yong Lee
    Dong Hoon Lee
    Japanese Journal of Ophthalmology, 2014, 58 : 146 - 154
  • [2] Bevacizumab Versus Ranibizumab in the Treatment of Macular Edema Due to Retinal Vein Occlusion: 6-Month Results of the CRAVE Study
    Rajagopal, Rithwick
    Shah, Gaurav K.
    Blinder, Kevin J.
    Altaweel, Michael
    Eliott, Dean
    Wee, Raymond
    Cooper, Blake
    Walia, Harpreet
    Smith, Bradley
    Joseph, Daniel P.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (08): : 844 - 850
  • [3] Comparing bevacizumab, ranibizumab, and aflibercept for early reduction of macular edema in patients with retinal vein occlusions (RVO).
    Jansen, Michael Eric
    Tyler, Lyndon
    Kermany, Daniel
    Waters, Jana
    Singer, Michael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [4] The efficacy of intravitreal ranibizumab for the treatment of macular oedema secondary to retinal vein occlusions in a treatment-naive cohort: 6-month outcomes
    Laginaf, Masara
    Lewis, Adam
    Chandran, Manju
    Menon, Geeta
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [5] Treatment Results of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
    Choi, Yu-Jin
    Choi, Young Je
    Cho, Yong Wun
    Yoo, Woong-Sun
    Chung, In Young
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2021, 62 (09): : 1207 - 1217
  • [6] Real-world outcomes of ranibizumab treatment in French patients with visual impairment due to Macular Edema secondary to Retinal Vein Occlusion: 24-month results from the BOREAL-RVO study.
    Glacet-Bernard, Agnes
    Girmens, Jean-Francois
    Kodjikian, Laurent
    Delcourt, Cecile
    Fajnkuchen, Franck
    Creuzot-Garcher, Catherine
    Massin, Pascale
    San Nicolas, Nathalie
    OPHTHALMIC RESEARCH, 2023, 66 (01) : 824 - 834
  • [7] Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular edema secondary to retinal vein occlusions
    Wai, Karen M.
    Khan, Mehnaz
    Silva, Fabiana
    Srivastava, Sunil K.
    Ehlers, Justis P.
    Rachitskaya, Aleksandra
    Kaiser, Peter K.
    Schachat, Andrew
    Babiuch, Amy
    Yuan, Alex
    Singh, Rishi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [8] Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion SCORE2 Study Report 4
    Scott, Ingrid U.
    VanVeldhuisen, Paul C.
    Ip, Michael S.
    Blodi, Barbara A.
    Oden, Neal L.
    King, Jacqueline
    Antoszyk, Andrew N.
    Peters, Mark A.
    Tolentino, Michael
    JAMA OPHTHALMOLOGY, 2017, 135 (06) : 639 - 649
  • [9] COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION 6-MONTH RESULT
    Terashima, Hiroko
    Hasebe, Hiruma
    Okamoto, Fumiki
    Matsuoka, Naoki
    Sato, Yayoi
    Fukuchi, Takeo
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (07): : 1377 - 1384
  • [10] Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to macular edema secondary to central retinal vein occlusion: 6-month results from the 24-month BOREAL-CRVO study
    Srour, Mayer
    Glacet, Agnes
    Girmens, Jean-Francois
    Kodjikian, Laurent
    DelCourt, Cecile
    Fajnkuchen, Frank
    Garcher, Catherine P. Creuzot
    Massin, Pascale
    Guillausseau, Pierre-Jean
    Ponthieux, Anne
    Finzi, Laetitia
    Grelaud-Boussinot, Angela
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)